10-Q: Cyanotech Reports 15% Increase in Net Sales Driven by Astaxanthin Demand, Despite Lower Gross Profit in Q1 2025

Cyanotech's first quarter of fiscal year 2025 saw a 15% increase in net sales compared to the same period last year, primarily driven by increased demand for astaxanthin products, though gross profit declined due to higher production costs.

Summary

• Cyanotech Corporation reported a 14.6% increase in net sales for the first quarter of fiscal year 2025, reaching $5.898 million, compared to $5.146 million in the same quarter of the previous year.
• The increase in sales was primarily driven by higher demand for astaxanthin products, both in bulk and packaged forms, while spirulina sales saw a slight decrease.
• Gross profit for the quarter was $1.476 million, with a gross profit margin of 25.0%, down from $1.532 million and 29.8% in the prior year's first quarter.
• The decrease in gross profit margin was attributed to higher production costs resulting from lower production volumes over the past six quarters.
• Operating loss for the quarter was $1.041 million, an improvement from the $1.209 million loss in the same period last year.
• Net loss for the quarter was $1.202 million, or $0.17 per diluted share, compared to a net loss of $1.369 million, or $0.22 per diluted share, in the first quarter of fiscal year 2024.
• The company launched Hawaiian Spirulina gummies in May, expanding its product offerings.
• Cyanotech is focusing on managing production to meet changing demand and has secured preliminary financing to support this effort.
• As of June 30, 2024, the company had cash of $720,000 and working capital of $207,000.
• The company is seeking a waiver from its bank for debt covenant violations as of March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed results with a positive sales increase offset by a significant decrease in gross profit and ongoing financial challenges. The company is facing debt covenant issues and has a going concern warning, which negatively impacts the overall sentiment. While there are some positive developments, the financial risks and uncertainties are significant.

Positives

• Net sales increased by 14.6% year-over-year, driven by strong astaxanthin sales.
• Operating loss improved from $1.209 million to $1.041 million year-over-year.
• Net loss per diluted share improved from $0.22 to $0.17 year-over-year.
• The company launched a new product, Hawaiian Spirulina gummies, expanding its product line.
• The company has secured preliminary financing to meet market demand.
• The company is actively managing production and inventory to mitigate cash outflow.

Negatives

• Gross profit margin decreased from 29.8% to 25.0% due to higher production costs.
• The company experienced a net loss of $1.202 million for the quarter.
• The company's working capital decreased to $207,000 from $2.037 million at the end of the previous quarter.
• The company is seeking a waiver from its bank for debt covenant violations as of March 31, 2024.
• The company continues to experience a loss from operations.

Risks

• The company is not in compliance with certain debt covenants and is seeking a waiver from its bank.
• The company's ability to continue as a going concern is in doubt due to operating losses and negative cash flows.
• The company is reliant on funding sources to provide liquidity.
• The company's future results are subject to fluctuations due to various factors, including sales volumes, weather patterns, competition, and costs.
• The company's production volumes can be impacted by imbalances in the biological production systems.
• The company may need to raise additional capital to maintain optimal production levels and efficiencies.

Future Outlook

The company aims to stabilize production volume, rationalize market channel participation, and leverage core competencies, focusing on consumer products while exploring bulk sales opportunities. They expect extraction services to generate additional income. The company acknowledges that gross profit margins may be impacted by lower production volumes, input costs, and competition. They will focus on higher margin consumer products and strive for continuous improvements in processes and production methods to stabilize costs and production levels for the future. The company also notes that significant sales variability between periods may occur based on historical results.

Management Comments

• Matthew K. Custer, President and CEO, stated that the quarter's net sales increased 15% due to increased sales of Astaxanthin in both bulk and packaged markets.
• Custer also mentioned the launch of Hawaiian Spirulina gummies in May.
• Custer noted that lower production over the past six quarters resulted in higher costs and a decline in gross profit.
• Custer stated that the company has preliminarily secured financing to meet market demand.
• Custer expressed positivity about the future of the brand and consumer interest in sustainable, high-quality dietary supplements.

Industry Context

The company operates in the dietary supplement market, which is experiencing growing demand for natural and sustainable products. The company's focus on microalgae-based products aligns with this trend. The company faces competition from other producers of spirulina and astaxanthin, which can impact market prices and margins.

Comparison to Industry Standards

• Cyanotech's gross profit margin of 25.0% is lower than some of its competitors in the nutraceutical space, such as companies with established brands and higher production volumes.
• The company's operating loss of $1.041 million indicates that it is still working towards achieving profitability, which is a common challenge for smaller companies in the industry.
• The company's reliance on a few major customers for a significant portion of its revenue is a risk factor that is not uncommon in the industry, but it highlights the need for diversification.
• The company's debt levels and covenant violations are a concern, as many companies in the industry operate with less leverage.
• The company's focus on sustainable production methods and high-quality ingredients is a competitive advantage that aligns with consumer preferences in the industry.

Related Party Transactions

• The company has a loan facility with a related party that allows them to borrow up to $2.0 million on a revolving basis.
• The company has an outstanding balance of $1,000,000 on a related party note.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and debt covenant violations.
• Employees may be affected by cost-saving initiatives, including potential furloughs.
• Customers may benefit from the company's expanded product offerings and focus on quality.
• Suppliers may be impacted by the company's production management and inventory control efforts.
• Creditors may be concerned about the company's debt levels and ability to meet its obligations.

Next Steps

• The company will focus on managing production to meet changing demand.
• The company will continue to monitor cost savings initiatives.
• The company will seek a waiver from its bank for debt covenant violations.
• The company will continue to explore opportunities for bulk sales orders.
• The company will host a virtual broadcast on August 8, 2024, to respond to questions about its operating results.

Key Dates

Keywords

Astaxanthin, Spirulina, Microalgae, Dietary Supplements, Net Sales, Gross Profit, Operating Loss, Net Loss, Debt Covenants, Financial Results, Production Costs, Working Capital, Going Concern